Uptravi® (selexipag) injection – New formulation approval
July 30, 2021 - Janssen announced the FDA approval of Uptravi (selexipag) injection, for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH.
Download PDF
